

meroven



Est accra tation laboramus aux id solet mucus quo. Verear  
elastend ea sed, cu eos dolor accusamus.

# Company Profile



# C O N T E N T S

Director's Message .....	1
About Us .....	2
Mission, Vision and Values .....	3
Evidence Based Medicine .....	4
Orphan Diseases .....	5
Product Portfolio .....	6
Oncology .....	7
Gynecology .....	8
Nasal Drug Delivery .....	10
Urogynecology .....	11
Dermatology .....	12
Oral Drug Delivery .....	14
Tamper Proof Packaging .....	16
Locations .....	17

# DIRECTOR'S MESSAGE

---



At MEROVEN, we pride ourselves on helping every member of your family to lead productive, healthy and high quality lives. We constantly strive to offer a unique range of products – from prescription pharmaceuticals to over-the-counter treatments. Corporate Social Responsibility is very much part of MEROVEN's fabric – we invest in people and the environment through sponsorships and donations as well as compassionate care for those in need.


To best serve our clients we believe in establishing a range of international strategic partnerships to strengthen all activities from development and commercialization, product supply and marketing. We work continuously to consolidate a position as a leading generic pharmaceutical company, worldwide and as your trusted healthcare partner providing you the best in class products available.

Our knowledge, abilities, capability to innovate, productivity and our ingenuity enable us to be responsive to you and your family's needs. We want to be your first choice.

We have proven successful shortening the development and commercialization process along with swift marketing authorizations to introduce new products to our markets supported by a harmonized production and distribution capability.

We welcome you to contact us – whether to enquire about our products or to offer your thoughts as to how we can best serve you.

  
**John A Kiernan**



# ABOUT US

MEROVEN is an Irish-based company that manufactures and trades in medical, pharmaceutical, OTC and other healthcare products.

MEROVEN's Corporate Head Office is based in Dublin, Ireland with regional representative sales offices throughout MENA and in particular the GCC.

MEROVEN's scope of business includes the following commercial activities:

- Manufacturing pharmaceuticals
- Manufacturing healthcare products
- Trading in medical devices, durable medical goods and consumables.

MEROVEN has established strategic international partnerships with other leading companies in healthcare to support its vision. These partnerships span from USA, Canada, EU and the GCC. MEROVEN offers its clients western quality generic medicines that fill a niche, gap and/or offer innovative technologies for delivery.



## Mission

Living a healthy life.

Our basic task is to enable people to lead a healthy, good quality life. This we achieve through our rich range of products and services – with prescription pharmaceuticals, self-medication products, with cosmetic and animal health products, and with our health-resort services, with investment in people and the environment, and through sponsorship and donations.

## Vision

We are continually consolidating our position as one of the leading generic pharmaceutical companies worldwide.

We are achieving this on our own by strengthening the long-term business connections and by establishing partnerships in the fields of development, product supply and marketing.

## Values

### Speed and flexibility

Our knowledge, our abilities, our capability to innovate, our productivity and our ingenuity enable us to be fast. We want to be first. Not just in sales, but in discovering the markets' new needs. We can do this by successfully shortening the development process, swift acquisition of registration documentation and our harmonised production and distribution. With our responsiveness and the ability to adapt we overcome the obstacles in our path, be they of a marketing or legislative nature. We can cope with any and all challenges – regardless of the size and the site of the project. Using flexible solutions, we make sure our partners can rely on us.

# EVIDENCE BASED MEDICINE

---

**MEROVEN** from its early beginning has made all its products according to the most recent guidelines and according to the most advanced literature in reputable publications. Some of which are the European Association of Urology (EAU) guidelines, the National Comprehensive Cancer Network (NCCN), The American Society of Hematology (ASH), the British Journal of Urology International (BJUI), The American Urology Association and many others.



# ORPHAN DISEASES

---

## HOME OF **ORPHAN** DISEASES

### Rare diseases at a glance

Rare diseases are life-threatening or chronically debilitating conditions affecting less than 5 in 10,000 people in the EU. Most of these people suffer from diseases affecting less than 1 in 100,000 people.

Between 5,000 and 8,000 distinct rare diseases exist, affecting between 6% and 8% of the population in total – in other words, between 27 million and 36 million people in the EU.


On average, five new diseases are described every week in the medical literature.


Chronic Myeloid Leukemia and Bladder Pain Syndrome are among those orphan diseases that we at MEROVEN consider a challenging responsibility of delivering the best cure for such diseases.

Other Orphan diseases including spinal muscular atrophy, lysosomal storage disorders, patent ductus arteriosus (PDA), familial adenomatous polyposis (FAP) and cystic fibrosis's symptoms of such rare diseases may appear at birth or in childhood. More than half of rare diseases appear during adulthood, such as renal-cell carcinoma, glioma and acute myeloid leukaemia.

As much as 80% of rare diseases are identified as being of genetic origin and affect between 3% and 4% of births. Other rare diseases are due to degenerative and proliferative causes.

# PRODUCT PORTFOLIO





## Chronic Myeloid Leukemia

**Chronic Myeloid Leukaemia (CML)** is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes. These cells, sometimes called blasts or leukaemic blasts, gradually crowd the bone marrow, interfering with normal blood cell production. **Mer-418™** is a patent NCE that is used as first line and second line therapy for CML and is compared to Imatinib, Dasatinib and Nilotinib with superiority in many parameters. **Mer-418™** molecule is an evidence based medicine with publications in the reliable American Society of Hematology.

Merotinib™ 100, 200, 300 & 400mg

NCCN guidelines 2018

American Society of Hematology

**Merotinib™** our Imatinib brand is the only product that meets National Comprehensive Cancer Network guidelines for Imatinib intolerant patients. **Merotinib™** is the first to be launched as 300mg dosage. We also have the widest **Merotinib™** range of 100mg, 200mg, 300mg & 400mg.





## Merogyne™-C

### Treatment for BACTERIAL VAGINOSIS

Treatment for Bacterial Vaginosis


Prevents BV recurrence

6 Day Course

- MEROGYNE-C 250 mg is a vaginal treatment for BV used once daily for 6 days.
- The efficacy for such is comparable to be as effective as metronidazole 0.75% vaginal gel for 5 days or metronidazole oral 500 mg for 7 days.
- It doesn't have systemic adverse events.
- Treatment for BACTERIAL VAGINOSIS.
- Prevents BV recurrence.
- It had been tested during prgnancy.

# GYNECOLOGY

Refracta is a vaginal therapy for VULVOVAGINAL CANDIDIASIS. It regulates and restores the optimum pH within the vagina and accordingly prevents the overgrowth of pathogens.



## Refracta™

### Treatment for VULVOVAGINAL CANDIDIASIS

Azole Resistant Candida

Negligible bioavailability

No Systemic Adverse Events

#### 1st week

SUN	MON	TUE	WED	THU	FRI	SAT

#### 2nd week

SUN	MON	TUE	WED	THU	FRI	SAT



Vulvovaginal Candidiasis  
Bacterial Vaginosis

# NASAL DRUG DELIVERY



## Intranasal Technology

Ketorolac

Metoclopramide

Midazolam

Nasal administration is a route in which drugs are delivered through the nose. The nasal cavity is covered by a thin mucosa which is well vascularised. Therefore, a drug molecule can be transferred quickly across the single epithelial cell layer directly to the systemic blood circulation without first-pass hepatic and intestinal metabolism. The effect is often reached within 5 min for smaller drug molecules thus a quite fast onset.

# UROGYNECOLOGY

**Bladder pain syndrome (BPS)** is the occurrence of persistent or recurrent pain perceived in the urinary bladder region, accompanied by at least one other symptom, such as pain worsening with bladder filling and day-time and/or night-time urinary frequency. There is no proven infection or other obvious local pathology. The ingredient of Accyst™ that is Pentosan Polysulfate Sodium has grade A recommendation in the treatment of (BPS).

**Prostate Pain Syndrome (PPS)** is the occurrence of persistent or recurrent episodic pain (which is convincingly reproduced by prostate palpation). There is no proven infection or other obvious local pathology. The ingredient of Accyst™ that is Pentosan Polysulfate Sodium has grade A recommendation in the treatment of (PPS).


## Accyst™

### Treatment for Pelvic Pain Syndrome

EAU Guidelines 2017

Oral and Intravesical range

Grade A recommendation



- Bladder pain syndrome (BPS)
- Prostate pain syndrome (PPS)
- NMIBC palliative therapy



# DERMATOLOGY

Psoriasis is an autoimmune disease that causes raised, red, scaly patches to appear on the skin. It typically affects the outside of the elbows, knees or scalp, though it can appear on any location. Some people report that psoriasis is itchy, burns and stings. Psoriasis is associated with other serious health conditions, such as diabetes, heart disease and depression. Acitretin and Fumaric acid esters have been extensively in the successful treatment of Psoriasis. Regarded as having good efficacy and safety profiles they are widely recommended in the medical literature and by international dermatology treatment guidelines.



## Psoriasis and Rosacea

Fumaric Acid esters

Acitretin

Doxycycline Monohydrate





# DERMATOLOGY

**Fumaven™**

Treatment for  
**PSORIASIS**

Fumaric Acid esters

AAD guidelines

European guidelines

Psoriasis is an autoimmune disease that causes raised, red, scaly patches to appear on the skin. It is recommended in the medical literature and by international dermatology treatment guidelines.



**Psoriasis**

First line therapy in Germany  
for **Psoriasis**  
**Level 1** evidence  
as per the **American Academy**  
of **Dermatology**

*First line in moderate  
to severe cases*

# ORAL DRUG DELIVERY

---


Orally fast dissolving films are a new approach to oral drug delivery technology. The fast dissolving films are gaining interest as an alternative to oral tablets, capsules or effervescent dosage forms. The films are designed to dissolve upon contact with a wet surface, such as the tongue, within a few seconds, meaning the consumer can take the product without need for additional liquid. Our portfolio of oral films includes:

## Oral Film Technology

Tadalafil

Ondansetron

Vitamin D3



# VITAMIN-D



## Spee-D™

### ORAL FILM TECHNOLOGY

Spee-D

Spee-D Children

## Spee-D™ *Children* Spee-D™

### Once Weekly

**D**  
Vitamin D  
IS REALLY A  
HORMONE

Most reliable form:  
**Vitamin D3** (cholecalciferol)

ONCE WEEKLY FOR CHILDREN  
**14,000  
IU**

ONCE WEEKLY FOR ADULTS  
**50,000  
IU**

Persistent pain is associated with vitamin D bone demineralisation, myopathy and musculoskeletal pain.

Pain pathways associated with cortical, immunological, hormonal and neuronal changes are potentially also influenced by vitamin D levels.

Vitamin D levels have been found to be low in groups of patients with various pain states.

# TAMPER PROOF PACKAGING

## FIRST TO FOLLOW **EUROPEAN DIRECTIVE**




Our patient's safety is foremost in our minds and MEROVEN is an early adopter of the upcoming EU legislation against falsified medicines. The European Medicine Agency (EMA) has taken measures to help protect patients from falsified medicines and has set new regulations that introduce 'safety features' on packaging of medicines for human use.

The EMA and the European Commission have prepared an implementation plan for centrally authorized medicines, to guide applicants and marketing-authorization holders in meeting the requirements of the new Falsified Medicines Directive.

In early compliance with these regulations, MEROVEN has introduced two safety features, a unique identifier (2-dimensional barcode) and an anti-tampering device, to be placed on packaging. While enforcement of these regulations are not scheduled until early 2019, MEROVEN is among the leading manufacturers to adopt such safety features on its packaging of prescription medicines.

# LOCATIONS



● Local Offices    ● Distributors    ● Under Registrations



**Ireland:**

**Meroven Limited**  
88 Harcourt St.  
Dublin 2  
D02 DK18  
Ireland  
Tel.: +353 16915505

**USA:**

**Meroven Limited**  
280 Madison Avenue  
9th Floor - Room 912  
New York, US  
NY 10016  
Tel.: +1 845 213-3442

**Australia:**

**Meroven Limited**  
Level 26, 1 Bligh Street  
Sydney, NSW, 2000  
Australia  
Tel.: +61 2 80467505

**UAE:**

**Meroven Limited**  
Business Center 1st floor  
Dubai World Central  
Dubai Logistics City, Dubai  
Tel.: +971 4 319 9148

**Netherlands:**

**Meroven Limited**  
Winthintlaan 200  
Utrecht  
3526 KV  
Netherlands